Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline

This article was originally published in The Tan Sheet

Executive Summary

Firm is proposing to close three former Block Drug consumer health care product manufacturing sites in Puerto Rico, UK, Ireland over next two years. Operations at these sites are duplicated elsewhere in GSK's network, company says, and can be incorporated into GSK facilities in UK, U.S. Three sites manufacture dental products such as Sensodyne, Poli-Grip, Polident and other smaller brands. GSK completed its purchase of Block in January (1"The Tan Sheet" Jan. 22, In Brief). Block's products eventually will bear GSK name

You may also be interested in...



GlaxoSmithKline

U.S. Consumer Healthcare business considering expansion of Kennedy Twp., Penn. facilities near Pittsburgh or relocation. Firm says SmithKline Beecham/Glaxo Wellcome merger, subsequent Block Drug acquisition are driving need for more office space. GSK previously said it would close three former Block manufacturing sites in Puerto Rico, UK, Ireland over next two years and incorporate operations into GSK facilities (1"The Tan Sheet" June 25, In Brief)

GlaxoSmithKline

U.S. Consumer Healthcare business considering expansion of Kennedy Twp., Penn. facilities near Pittsburgh or relocation. Firm says SmithKline Beecham/Glaxo Wellcome merger, subsequent Block Drug acquisition are driving need for more office space. GSK previously said it would close three former Block manufacturing sites in Puerto Rico, UK, Ireland over next two years and incorporate operations into GSK facilities (1"The Tan Sheet" June 25, In Brief)

GlaxoSmithKline

U.S. Consumer Healthcare business considering expansion of Kennedy Twp., Penn. facilities near Pittsburgh or relocation. Firm says SmithKline Beecham/Glaxo Wellcome merger, subsequent Block Drug acquisition are driving need for more office space. GSK previously said it would close three former Block manufacturing sites in Puerto Rico, UK, Ireland over next two years and incorporate operations into GSK facilities (1"The Tan Sheet" June 25, In Brief)

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel